Real-World Outcomes of Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia
Özet
Background: Chronic lymphocytic leukemia (CLL) is a biologically heterogeneous disease characterized by variable clinical outcomes. The introduction of targeted therapies, particularly the BCL-2 inhibitor venetoclax, has significantly improved treatment outcomes in patients with relapsed/refractory (R/R) CLL. However, real-world data on the safety and effectiveness of venetoclax-based regimens remain limited. Methods: In this multicenter retrospective study, 147 adult patients with R/R CLL treated with venetoclax between April 2019 and August 2025 were analyzed. Venetoclax was administered as monotherapy or in combination with rituximab, obinutuzumab, or ibrutinib. Adverse events were graded according to CTCAE v4.0, and treatment responses were assessed based on IWCLL criteria. Survival outcomes, including overall survival (OS) and progression-free survival (PFS), were evaluated using Kaplan–Meier analysis. Results: The median age at venetoclax initiation was 64 years, and patients had received a median of two prior lines of therapy. Combination therapy was administered in 78.9% of patients. The overall response rate was 83.0%, including complete remission in 65.3% of patients. Grade ≥ 3 hematologic adverse events included neutropenia (18.4%), thrombocytopenia (14.3%), and anemia (7.5%). Tumor lysis syndrome (TLS) occurred in 28.6% of patients, predominantly during the dose ramp-up phase. At a median follow-up of 61 months, median OS and PFS were both 60 months. Bulky disease was associated with inferior survival outcomes. Conclusions: Venetoclax-based therapy is effective and well tolerated in patients with R/R CLL in a real-world setting. High response rates and durable survival outcomes were observed despite the inclusion of patients with high-risk clinical and biological features. These findings support the use of venetoclax as a key component of modern CLL treatment strategies and highlight the importance of real-world evidence in optimizing patient management.
Anahtar kelimeler
Atıf için künye
Odabasi Giden, A., Özatlı, D., ERKURT, M. A., Karakus, A., Sincan, G., Hindilerden, F., Bilen, Y., Hatipoglu, U., Akgun Cagliyan, G., Hacibekiroglu, T., Demircioglu, S., Yanardag Acik, D., Demir, C., Katircilar, Y., Tombak, A., Yilmaz, S., Kuku, I., Erdem, F., Ozturkmen, A. Y., … ALTUNTAŞ, F. (2026). Real-World Outcomes of Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia. Hemato, 7(2). https://doi.org/10.3390/hemato7020016
BibTeX
@article{odabasigiden2026-227800,
author = {Odabasi Giden, Asli and Özatlı, Düzgün and ERKURT, MEHMET ALİ and Karakus, Abdullah and Sincan, Gülden and Hindilerden, Fehmi and Bilen, Yusuf and Hatipoglu, Ugur and Akgun Cagliyan, Gulsum and Hacibekiroglu, Tuba and Demircioglu, Sinan and Yanardag Acik, Didar and Demir, Cengiz and Katircilar, Yavuz and Tombak, Anil and Yilmaz, Seda and Kuku, Irfan and Erdem, Fuat and Ozturkmen, Asli Yuksel and Dal, Mehmet Sinan and BAŞCI, SEMİH and Korkmaz, Serdal and Ulas, Turgay and ALTUNTAŞ, FEVZİ},
title = {Real-World Outcomes of Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia},
journal = {Hemato},
year = {2026},
volume = {7},
number = {2},
issn = {2673-6357},
doi = {10.3390/hemato7020016},
url = {https://akademik.atauni.edu.tr/yayinlar/227800-real-world-outcomes-of-venetoclax-in-relapsedrefractory-chronic-lymphocytic}
}